RESEARCH LETTERS

3. Dong N, Fang L, Zeng S, Sun Q, Chen H, Xiao S. Porcine deltacoronavirus in mainland China. Emerg Infect Dis. 2015;21:2254–5. http://dx.doi.org/10.3201/eid2112.150283

4. Theuns S, Vyt P, Desmarets LM, Roukaerts ID, Heylen E, Zeller M, et al. Presence and characterization of pig group A and C rotaviruses in feces of Belgian diarrheic suckling piglets. Virus Res. 2016;213:172–83. http://dx.doi.org/10.1016/j.virusres.2015.12.004

5. Reuter G, Boros A, Pankovics P. Kobuviruses—a comprehensive review. Rev Med Virol. 2011;21:32–41. http://dx.doi.org/10.1002/rmv.677

6. Lau SK, Woo PC, Li KS, Huang Y, Wang M, Lam CS, et al. Complete genome sequence of bat coronavirus HKU2 from Chinese horseshoe bats revealed a much smaller spike gene with a different evolutionary lineage from the rest of the genome. Virology. 2007;367:428–39. http://dx.doi.org/10.1016/j.virol.2007.06.009

Address for correspondence: Zhifen Wen, Guangdong Wen's Group Academy, Guangdong Wen's Foodstuffs Group Co., Ltd., Yunfu 527400, China; email: wenzhifen@163.com; Yongchang Cao, Life Sciences School, Sun Yat-sen University, Higher Education Mega Center, Guangzhou 510006, China; email: caoych@mail.sysu.edu.cn

Antimicrobial Drug–Resistant Shiga Toxin–Producing *Escherichia coli* Infections, Michigan, USA

Sanjana Mukherjee, Rebekah E. Mosci, Chase M. Anderson, Brian A. Snyder, James Collins, James T. Rudrik, Shannon D. Manning

Author affiliations: Michigan State University, East Lansing, Michigan, USA (S. Mukherjee, R.E. Mosci, C.M. Anderson, B.A. Snyder, S.D. Manning); Michigan Department of Health and Human Services, Lansing (J. Collins, J.T. Rudrik)

High frequencies of antimicrobial drug resistance were observed in O157 and non-O157 Shiga toxin–producing *E. coli* strains recovered from patients in Michigan during 2010–2014. Resistance was more common in non-O157 strains and independently associated with hospitalization, indicating that resistance could contribute to more severe disease outcomes.

Shiga toxin–producing *Escherichia coli* (STEC) contributes to 265,000 cases of foodborne illness annually in the United States (*1*). Most infections are caused by O157 strains; however, non-O157 STEC infections have increased (*2*). Antimicrobial drug resistance among STEC has been reported (*3–5*) but is probably underestimated. Given the importance of resistance in *E. coli* pathotypes, we sought to determine the prevalence of resistant STEC infections and assess the effects of resistance on disease.

We obtained 358 STEC isolates from the Michigan Department of Health and Human Services (MDHHS) Reference Laboratory (Lansing, MI, USA), collected during 2010–2014. Of these, 14 were outbreak associated. We examined 1 strain per outbreak using protocols approved by Michigan State University (MSU; Lansing, MI, USA; IRB #10-736SM) and MDHHS (842-PHALAB). Overall, 31 (8.8%) strains (23 non-O157, 8 O157) were resistant to antimicrobial drugs (Table). Resistance to ampicillin (7.4%) was most common, followed by trimethoprim/sulfamethoxazole (SXT) (4.0%) and ciprofloxacin (0.3%). Compared with national rates, resistance to ampicillin and SXT was higher, but not significantly different, for O157 isolates from Michigan (online Technical Appendix Figure 1, https://wwwnc.cdc.gov/EID/article/23/9/17-0523-Techapp1.pdf) (*6*). One strain was resistant to all drugs, and all resistant strains had high MICs (ampicillin, >64 µg/mL; ciprofloxacin, >32 µg/mL; SXT, in 1:19 ratio, >32/608 µg/mL). Notably, resistance was twice as common for non-O157 (11.1%) than for O157 (5.5%) strains. O111 strains (n = 7) had significantly higher resistance frequencies (24.1%) than other non-O157 serogroups (p = 0.03). We found variation by year and season; resistance frequencies were highest in 2012 (online Technical Appendix, Figure 2) and during winter/spring (online Technical Appendix Table 1), but neither trend was significant. We also observed a strong but nonsignificant association between resistance and hospitalization but no association for urban versus rural residence (*7*) or county after stratifying by prescription rates (*8*) in the univariate analyses.

We conducted a multivariate analysis using logistic regression, with hospitalization as the dependent variable; we included variables with significant (p≤0.05) and strong (p≤0.20) associations from the univariate analysis as independent variables. Forward selection indicated that hospitalized patients were more likely to have resistant infections (odds ratio [OR] 2.4, 95% CI 1.00–5.82) and less likely to have non-O157 infections (OR 0.4, 95% CI 0.21–0.61) (online Technical Appendix Table 2), suggesting that resistant infections or O157 infections may cause more severe clinical outcomes. Patients ≥18 years of age, women, and patients with bloody diarrhea were also more likely to be hospitalized.

Although we found no significant difference by *stx* profile, strains possessing *stx*1 only were more commonly resistant than strains with *stx*2 alone (p = 0.27 by Fisher exact test). All 23 (100%) resistant non-O157 STEC and 1

Table. Antimicrobial drug resistance in 353 clinical Shiga toxin–producing *Escherichia coli* isolates, by serotype, Michigan, USA, 2010–2014*

Serotype	No. isolates	No. (%) isolates			
		Any resistance	Ampicillin resistance	Ciprofloxacin resistance	SXT resistance
O157	146	8 (5.5)	7 (4.8)	0 (0)	5 (3.4)
Non-O157	207	23 (11.1)	19 (9.2)	1 (0.5)	9 (4.3)
O26	53	4 (7.6)	4 (7.6)	0 (0)	1 (1.9)
O45	50	6 (12.0)	5 (10.0)	0 (0)	2 (4.0)
O103	75	6 (8.0)	5 (6.7)	1 (1.3)	4 (5.3)
O111	29	7 (24.1)	5 (17.2)	0 (0)	2 (6.9)

*We tested 358 isolates by disk diffusion for resistance to ampicillin (10 µg in disk), SXT (25 µg in disk), and ciprofloxacin (5 µg in disk). MICs were determined by using Etest. Strains were classified as resistant or susceptible according to Clinical Laboratory Standards Institute guidelines; *E. coli* ATCC 25922 was used as a control. Five isolates had unknown serotypes and were excluded from analysis. Isolate numbers for individual antibiotics do not always add up to the total number of isolates with any resistance because some isolates were resistant to >1 drug. SXT, trimethoprim/ sulfamethoxazole.

(12.5%) resistant O157 strain had *stx*1 only. Strains positive for *eae* were less likely to be resistant (n = 27; 8.4%) than *eae*-negative strains (n = 4; 23.5%); this nonsignificant difference (p = 0.07 by Fisher exact test) could be due to small sample sizes. All 8 resistant O157 strains and 18 (78.3%) of 23 resistant non-O157 strains had *eae*, demonstrating correlations between virulence genes and serogroups.

Overall, we detected a high frequency of resistance among non-O157 STEC (11.2%), similar to findings from Mexico (15%), although we evaluated fewer drugs (*5*). Resistance to ciprofloxacin was low despite its routine use for treating enteric infections, perhaps because resistance development in *E. coli* requires multiple mutations (*9*). Resistance frequencies in STEC were low relative to other *E. coli* pathotypes such as extraintestinal *E. coli*, which may be attributable to differences in the source of the infections (*3*).

The higher O157 resistance frequencies in Michigan than nationwide indicate that selection pressures vary by location and source. Although we observed no difference in resistance frequencies for counties with high versus low antimicrobial drug prescription rates (*8*), we have not investigated selection pressures from drug use in farm environments that may affect resistance emergence in Michigan. Approximately 12×10^6 kg of antimicrobial drugs are administered to food animals annually in the United States; roughly 61% of these are medically relevant. Higher resistance frequencies in winter/spring (12.2%) than summer/ fall (7.5%) could be attributed to variation in prescription rates by season (*10*).

Because Michigan is not part of the Centers for Disease Control and Prevention Foodborne Diseases Active Surveillance Network and resistance in STEC has not been widely researched, data about the prevalence and impact of resistance are lacking. This study detected a high frequency of STEC resistance to antimicrobial drugs commonly used in human and veterinary medicine, particularly for non-O157 serotypes, which have increased in frequency (*2*). Monitoring resistance in STEC is essential because of the risk of transmitting resistant strains from food animals to humans and the high likelihood of horizontal transfer of resistance genes from STEC to other pathogens. Routine monitoring can uncover new treatment approaches and guide development of strategies for controlling emergence and spread of resistance in STEC and other *E. coli* pathotypes.

Miss Mukherjee is a PhD student in the Department of Microbiology and Molecular Genetics at MSU. She is studying antimicrobial drug resistance in STEC and nontyphoidal *Salmonella*. Her primary research interests are molecular epidemiology and medical microbiology.

References

1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States— major pathogens. Emerg Infect Dis. 2011;17:7–15. http://dx.doi.org/10.3201/eid1701.P11101
2. Tseng M, Sha Q, Rudrik JT, Collins J, Henderson T, Funk JA, et al. Increasing incidence of non-O157 Shiga toxin-producing *Escherichia coli* (STEC) in Michigan and association with clinical illness. Epidemiol Infect. 2016;144:1394–405. http://dx.doi.org/10.1017/S0950268815002836
3. Schroeder CM, Meng J, Zhao S, DebRoy C, Torcolini J, Zhao C, et al. Antimicrobial resistance of *Escherichia coli* O26, O103, O111, O128, and O145 from animals and humans. Emerg Infect Dis. 2002;8:1409–14. http://dx.doi.org/10.3201/eid0812.0200770
4. Mora A, Blanco JE, Blanco M, Alonso MP, Dhabi G, Echeita A, et al. Antimicrobial resistance of Shiga toxin (verotoxin)– producing *Escherichia coli* O157:H7 and non-O157 strains isolated from humans, cattle, sheep and food in Spain. Res Microbiol. 2005;156:793–806. http://dx.doi.org/10.1016/j.resmic.2005.03.006
5. Amézquita-López BA, Quiñones B, Soto-Beltrán M, Lee BG, Yambao JC, Lugo-Melchor OY, et al. Antimicrobial resistance profiles of Shiga toxin-producing *Escherichia coli* O157 and

non-O157 recovered from domestic farm animals in rural communities in northwestern Mexico. Antimicrob Resist Infect Control. 2016;5:1–6. http://dx.doi.org/10.1186/s13756-015-0100-5

6. Centers for Disease Control and Prevention. NARMS now: human data 2016 [cited 2016 Oct 12]. http://wwwn.cdc.gov/narmsnow/

7. Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. Vital Health Stat 2. 2014;(166):1–73.

8. Center for Healthcare Research and Transformation. Antibiotic prescribing and use. 2011 [cited 2016 Oct 12]. http://www.chrt.org/document/antibiotic-prescribing-and-use/

9. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120–6. http://dx.doi.org/10.1086/428052

10. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Taylor TH. Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. Antimicrob Agents Chemother. 2014;58:2763–6. http://dx.doi.org/10.1128/AAC.02239-13

White-Nose Syndrome Fungus in a 1918 Bat Specimen from France

Michael G. Campana, Naoko P. Kurata, Jeffrey T. Foster, Lauren E. Helgen, DeeAnn M. Reeder, Robert C. Fleischer, Kristofer M. Helgen

Author affiliations: Smithsonian Institution, Washington, DC, USA (M.G. Campana, N.P. Kurata, L.E. Helgen, R.C. Fleischer); University of New Hampshire, Durham, New Hampshire, USA (J.T. Foster); Bucknell University, Lewisburg, Pennsylvania, USA (D.M. Reeder); University of Adelaide, Adelaide, South Australia, Australia (K.M. Helgen)

White-nose syndrome, first diagnosed in North America in 2006, causes mass deaths among bats in North America. We found the causative fungus, *Pseudogymnoascus destructans*, in a 1918 sample collected in Europe, where bats have now adapted to the fungus. These results are consistent with a Eurasian origin of the pathogen.

We report the earliest known historical incidence of the fungus *Pseudogymnoascus* (formerly *Geomyces*) *destructans*, detected in a museum specimen of a bat (*Myotis bechsteinii*) collected in France in 1918. This fungal pathogen causes white-nose syndrome (WNS) in bats (*1*). Since its introduction into eastern North America around 2006, WNS has devastated bat populations across the continent (*2*). *P. destructans* has also been found across the Eurasian landmass (*3,4*) without documented mass bat deaths. Epidemiologic evidence among bats and fungal genetics indicate that the fungus has been recently introduced into North American bat populations (*5–7*).

To clarify the epidemiologic history of WNS and to investigate physical evidence of its presence in specific locations in the past, we screened 138 19th- and 20th-century bat specimens (housed at the National Museum of Natural History [USNM], Washington, DC) from North America (n = 41), Europe (n = 83), and East Asia (n = 14) for *P. destructans* DNA (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/23/9/17-0875-Techapp1.pdf). We sampled dry museum skins and intact bodies stored in 70% ethanol; some were originally fixed in formalin. We swabbed bat rostra and wings to collect potentially preserved *P. destructans* biomolecules and stored swabs in 100% ethanol until DNA extraction.

We extracted DNA in a dedicated ancient DNA laboratory at the National Zoological Park (Washington, DC) by using stringent protocols to prevent false positive results from modern DNA contamination (*8*). Before extraction, we removed swabs from the ethanol and let them air dry. We then let swabs digest overnight at 55°C in 600 μL extraction buffer (1× Tris-EDTA buffer, pH 8.0, 0.019 mmol/L EDTA, 0.01 mmol/L NaCl, 1% SDS, 10 mg/mL DTT, and 1 mg/mL proteinase K) (*8*). Later extractions omitted DTT. We extracted digested samples twice in 600 μL phenol and once in 600 μL chloroform. We removed and concentrated the aqueous phase by using Amicon Ultra-4 30 kDA molecular weight cutoff columns (Millipore Sigma, Merck, Billerica, MA, USA) to a final volume of ≈250 μL. We included 1 extraction blank for every 10–11 historical samples.

We screened extracts for *P. destructans* by using a previously described species-specific quantitative PCR targeting 103 bp (including primers) of the intergenic spacer region (*9*). Each extract was amplified in 2–8 replicate PCRs. Multiple, no-template controls (*2,3*) were included in each PCR setup. Positive products from experiments in which quantifiable contamination (>0.1 genome equivalents/μL sample) was observed in ≥1 negative control were discarded; these experiments were repeated with fresh reagents.

One sample (USNM 231170) tested positive in 2 of 3 PCRs. We performed a second independent extraction on this sample. The replicate extraction tested positive in 4 of 5 PCRs. Two of the USNM 231170–positive PCR products were confirmed by using Sanger sequencing and comparison to publicly available *P. destructans* sequences in GenBank. These sequences were 100% identical to *P. destructans* sequences from North America (GenBank accession nos. JX270192.1

Antimicrobial Drug–Resistant Shiga Toxin–Producing *Escherichia coli* Infections, Michigan, USA

Technical Appendix

Technical Appendix Table 1. Univariate analysis highlighting factors associated with antibiotic resistance in 358 clinical Shiga toxin–producing *Escherichia coli* (STEC) in Michigan, 2010–2014

Characteristic	Total strains*	No (%) resistant	OR (95% CI†)	p-value‡
Pathogen factors				
Serotype				
O157	146	8 (5.5)	1.0	–
Non-O157	207	23 (11.1)	2.2 (0.94–4.97)	0.066
stx profile				
*stx*1	205	25 (12.2)	1.9 (0.72–5.28)	0.18
*stx*2	75	5 (6.7)	1.0	–
stx1,stx2	77	2 (2.6)	0.3 (0.07–1.99)	0.27
eae presence				
Yes	323	27 (8.4)	0.3 (0.10–1.04)	0.05
No	18	4 (22.2)	1.0	–
Outbreak associated				
Yes	14	1 (7.1)	0.8 (0.10–6.14)	0.81
No	344	31 (9.0)	1.0	–
Demographics and other factors				
Residence				
Urban	153	13 (8.5)	0.9 (0.43–1.90)	0.80
Rural	205	19 (9.3)	1.0	–
Age, y				
0–18	154	12 (7.8)	1.0	–
19–64	172	17 (9.9)	1.3 (0.60–2.81)	0.51
≥65	32	3 (9.4)	1.2 (0.32–4.61)	0.76
Sex				
Male	173	14 (8.1)	1.0	–
Female	185	18 (9.7)	1.2 (0.59–2.54)	0.59
Antimicrobial-drug prescription rates by county				
High	109	13 (11.9)	1.6 (0.78–3.45)	0.19
Low	249	19 (7.6)	1.0	–
Season				
Winter and spring	115	14 (12.2)	1.7 (0.83–3.62)	0.14
Summer and fall	243	18 (7.4)	1.0	–
Clinical factors				
Abdominal pain				
Yes	279	27 (9.7)	1.4 (0.48–4.23)	0.53
No	57	4 (7.0)	1.0	–
Body ache				
Yes	55	7 (12.7)	1.6 (0.64–3.83)	0.33
No	281	24 (8.5)	1.0	–
Bloody diarrhea				
Yes	232	21 (9.1)	0.9 (0.42–2.06)	0.87
No	104	10 (9.6)	1.0	–
Hemolytic uremic syndrome (HUS)				
Yes	6	0 (0)	–	1.0
No	331	31 (9.4)	–	
Hospitalization				
Yes	106	13 (12.3)	1.7 (0.80–3.61)	0.16
No	237	18 (7.6)	1.0	–

*Epidemiological data and case information were retrieved from the Michigan Disease Surveillance System (MDSS). SAS 9.3 (SAS Institute, Cary, NC) and Epi Info™ 7 (CDC) were used for statistical analyses. Depending on the variable examined, the number of isolates do not add up to the total (n=358) because of missing data.

Characteristic	Total strains*	No (%) resistant	OR (95% CI†)	p-value‡

†95% confidence interval (CI) for odds ratio (OR)
‡*p*-value was calculated by Chi-square test,; Fisher exact test was used for variables ≤5 in at least 1 cell

Technical Appendix Table 2. Univariate and multivariate analyses to identify factors associated with hospitalization

| Characteristic	Total strains*	No (%) hospitalized	OR (95% CI)†	p-value‡
Serotype				
O157	138	63 (45.7%)	1.0	–
Non-O157	200	42 (21.0%)	0.3 (0.20–0.51)	<0.0001
stx profile				
*stx*1	198	43 (21.7%)	0.3 (0.18–0.58)	<0.0001
*stx*2	72	33 (45.8%)	1.0	–
stx1,stx2	72	30 (41.7%)	1.7 (0.86–3.20)	0.13
eae presence				
Yes	310	92 (29.7)	0.5 (0.20–1.50)	0.23
No	16	7 (43.8)	1.0	–
Outbreak associated				
Yes	14	7 (50.0)	2.5 (0.79–6.80)	0.11
No	329	99 (30.1)	1.0	–
Antimicrobial drug resistant isolate				
Yes	31	13 (41.9)	1.7 (0.80–3.61)	0.16
No	312	93 (29.8)	1.0	–
Sex				
Male	166	39 (23.5)	1.0	–
Female	177	67 (37.9)	2.0 (1.24–3.17)	0.004
Age, y				
0–18	145	35 (24.1)	1.0	–
19–64	167	56 (33.5)	1.6 (0.96–2.61)	0.07
≥65	31	15 (48.4)	2.9 (1.32– 6.56)	0.007
Abdominal pain				
Yes	277	95 (34.3)	2.2 (1.08–4.41)	0.03
No	57	11 (19.3)	1.0	–
Body ache				
Yes	55	20 (36.4)	1.3 (0.70–2.35)	0.42
No	279	86 (30.8)	1.0	–
Bloody diarrhea				
Yes	230	91 (39.6)	3.9 (2.12–7.13)	<0.0001
No	104	15 (14.4)	1.0	–
Hemolytic uremic syndrome (HUS)				
Yes	5	4 (80.0)	9.0 (0.99–81.45)	0.02
No	328	101 (30.8)	1.0	–
Multivariate logistic regression associations §				
Characteristic	OR	95% CI ¶	*p*-value	
Sex: F	1.9	1.15–3.32	0.02	
Age, y: 18	1.9	1.15–3.28	0.014	
Serogroup: non-O157	0.4	0.21–0.61	0.0002	
Antimicrobial drug resistant isolate: Yes	2.4	1.00–5.82	0.05	
Bloody diarrhea: Yes	3.9	1.99–7.65	<0.0001	

*Depending on the variable examined, the number of isolates do not add up to the total (n=358) because of missing data. All 6 HUS cases had O157 strains with *eae*, though 3 had *stx1,stx2* and the other 3 had *stx2* infections
†95% confidence interval (CI) for odds ratio (OR)
‡*p*-value was calculated by Chi-square test; Fisher exact test was used for variables ≤5 in at least 1 cell.
§Logistic regression was performed using forward selection while controlling for variables that yielded significant (P≤0.05) and strong (P≤0.20) associations with hospitalization in the univariate analysis. The model was adjusted for age, sex, serogroup, *stx* profile, outbreak status, resistance, HUS, and bloody diarrhea. Only those variables yielding significant associations are presented; Hosmer and Lemeshow Goodness-of-Fit test (P= 0.73). All variables were tested for collinearity.
¶Wald 95% confidence intervals (CI)

Technical Appendix Figure 1. Frequency of any resistance to ampicillin, ciprofloxacin and trimethoprim-sulfamethoxazole among O157 and non-O157 Shiga toxin producing *E. coli* (STEC) isolates recovered from patients in Michigan, 2010–2014

Technical Appendix Figure 2. Frequency of resistance to various antimicrobials among STEC O157 isolates in Michigan compared to those reported by the National Antimicrobial Resistance Monitoring System (NARMS), 2010-2014. Abbreviation: AMP, ampicillin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole